Internal Medicine Perspectives for Oncology Advanced Practice Providers:

The Basics of Cancer Immunotherapy and Immunology

Presented by Jason Luke, MD

UPMC Hillman Cancer Center, Shadyside

Learning Objectives

After this session participants will be able to:

• Recall the components, functioning, and mechanisms of the human immune system
• Verbalize understanding of the relationship between immunotherapy and cancer
• Identify immunity’s role within treatment principles of the oncologic patient

Contact Hours

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour.

Disclosure of Conflicts of Interest

All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following information was provided:

Jason Luke disclosed grant/research support (all to institution for clinical trials unless noted) from AbbVie, Agios (IIT), Array (IIT), Astellas, Bristol-Myers Squibb (IIT & industry), Corvus, EMD Serono, Immatics, Incyte, Kadmon, Macrogenics, Merck, Moderna, Nektar, Numab, Replimmune, Rubius, Spring bank, Synlogic, Takeda, Trishula, Tizona, Xencor; consultancy with Abbvie, Alnylam, Array, Bayer, Bristol-Myers Squibb, Checkmate, Cstone, Eisai, EMD Serono, KSQ, Janssen, Macrogenics, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon, Rubius, Silicon, Synlogic, TRex, Werewolf, Xilio, Xencor; stockholding with Spring Bank Actym; Other disclosures include scientific advisory board member for 7 Hills, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, Onc.AI, Pyxis, and Tempest, and patents existing with (both provisional) Serial #15/612,657 (Cancer Immunotherapy), and PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness:  Diagnostic, Prognostic and Therapeutic Uses Thereof).